U.S. Markets closed

At $49.41, Is HealthEquity Inc (NASDAQ:HQY) A Buy?

Renee Allred

HealthEquity Inc (NASDAQ:HQY), a healthcare company based in United States, saw a double-digit share price rise of over 10% in the past couple of months on the NasdaqGS. With many analysts covering the mid-cap stock, we may expect any price-sensitive announcements have already been factored into the stock’s share price. However, could the stock still be trading at a relatively cheap price? Let’s examine HealthEquity’s valuation and outlook in more detail to determine if there’s still a bargain opportunity. View our latest analysis for HealthEquity

What’s the opportunity in HealthEquity?

The stock is currently trading at $49.41 on the share market, which means it is overvalued by 86% compared to my intrinsic value of $26.52. This means that the buying opportunity has probably disappeared for now. But, is there another opportunity to buy low in the future? Since HealthEquity’s share price is quite volatile, this could mean it can sink lower (or rise even further) in the future, giving us another chance to invest. This is based on its high beta, which is a good indicator for how much the stock moves relative to the rest of the market.

Can we expect growth from HealthEquity?

NasdaqGS:HQY Future Profit Jan 10th 18

Future outlook is an important aspect when you’re looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Although value investors would argue that it’s the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. HealthEquity’s earnings over the next few years are expected to increase by 21.68%, indicating a highly optimistic future ahead. This should lead to more robust cash flows, feeding into a higher share value.

What this means for you:

Are you a shareholder? HealthEquity’s optimistic future growth appears to have been factored into the current share price, with shares trading above its fair value. At this current price, shareholders may be asking a different question – should I sell? If you believe HealthEquity should trade below its current price, selling high and buying it back up again when its price falls towards its real value can be profitable. But before you make this decision, take a look at whether its fundamentals have changed.

Are you a potential investor? If you’ve been keeping tabs on HealthEquity for some time, now may not be the best time to enter into the stock. The price has surpassed its true value, which means there’s no upside from mispricing. However, the optimistic prospect is encouraging for HealthEquity, which means it’s worth diving deeper into other factors in order to take advantage of the next price drop.

Price is just the tip of the iceberg. Dig deeper into what truly matters – the fundamentals – before you make a decision on HealthEquity. You can find everything you need to know about HealthEquity in the latest infographic research report. If you are no longer interested in HealthEquity, you can use our free platform to see my list of over 50 other stocks with a high growth potential.


To help readers see pass the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price sensitive company announcements.

The author is an independent contributor and at the time of publication had no position in the stocks mentioned.